跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NAT-ALPRAZOLAM - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NAT-ALPRAZOLAM
Authorized
STANDARD
NAT-ALPRAZOLAM
natco pharma (canada) inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
9acaa2fdcd43030c
Company
natco pharma (canada) inc
Type
Standard
Approval Details
Approval Id
9acaa2fdcd43030c
Drug Approval Canada Name
NAT-ALPRAZOLAM
Product Name
NAT-ALPRAZOLAM
Status
Cancelled Post Market
Status Date
2018-06-30
Original Market Date
2016-05-05
Din
02417669
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Targeted (CDSA IV)
Ahfs
28:24.08
Atc Original
N05BA12 ALPRAZOLAM
Atc Name
n 05 ba 12
Aig Number
0115008004
Company Name
natco pharma (canada) inc
Company Address
2000 Argentia Road, Plaza 1, Suite 200, Mississauga, Ontario, Canada, L5N 1P7
Active Ingredients
ALPRAZOLAM
2 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
9acaa2fdcd43030c
Type
Standard
Back to Health Canada Approvals